



# *The Use of a Rapid Syphilis Test with Specimens from an HIV Cluster Investigation in Rural West Virginia*

**Lara E. Pereira, Ph.D.**


Centers for Disease Control and Prevention | Division of STD Prevention

*2019 HIV Diagnostics Conference  
Atlanta, Georgia USA*


*\*No conflicts of interest or financial disclosures\**

# Syphilis in the United States

Syphilis – Rates of reported cases by stage of infection, U.S., 1941-2017



Distribution of primary and secondary syphilis by sex and sexual behavior, U.S., 2017




- Syphilis is a sexually transmitted infection that can progress to primary, secondary, latent (early, late) and tertiary stages if left untreated
- The total number of reported primary and secondary syphilis cases increased 10.5% from 2016 to 2017
  - Men ↑9.0%
  - Women ↑21.1%

# Diagnosis of Syphilis

- Causative agent: bacterial spirochete *Treponema pallidum* subsp *pallidum*
- Clinical history/evaluation
  - Primary syphilis: ulcers, chancres at the infection site
  - Secondary syphilis: skin rash, mucocutaneous lesions, lymphadenopathy
  - Latent: lack of clinical manifestations
  - Tertiary: cardiac, gummatous lesions, tabes dorsalis, general paresis
  - Neurosyphilis, ocular and otic symptoms
- Direct detection – focus on *T. pallidum*
  - Dark field microscopy
  - Polymerase chain reaction (PCR) / Nucleic acid amplification test (NAAT) - investigational
- Indirect detection – focus on humoral immune responses to *T.pallidum*
  - Nontreponemal assays
    - Detects antibodies targeting lipoidal antigens from damaged host cells and *T.pallidum* *T.pallidum* cell wall, host immune responses
    - Rapid plasma regain (RPR), Venereal Disease Research Laboratory (VDRL), automated instruments
  - Treponemal assays
    - Detects antibodies specific to *T.pallidum*
    - *Treponema pallidum* particle agglutination assay (TP-PA), Trep-Sure enzyme immunoassay (EIA), chemiluminescence immunoassays (CIA), automated EIA/CIA

# Current algorithms



# Rapid Syphilis Test

- Simple – minimal training
  - Portable – not limited to laboratory setting
  - Quick turnaround - Prevent loss to follow-up and facilitate immediate linkage to care/treatment
  - Cost-effective
- 
- Syphilis Health Check
    - Qualitative lateral flow immunochromatographic assay
    - The only FDA-cleared and CLIA-waived rapid syphilis test in the U.S.
    - Relatively new test (2011)
    - A need for improved understanding of test performance in various stages of syphilis, in context of co-infections (e.g. HIV), special and/or high risk populations



<https://www.trinitybiotech.com/products/syphilis-health-check-3/>


# Rapid Syphilis Test

- Simple – minimal training
  - Portable – not limited to laboratory setting
  - Quick turnaround - Prevent loss to follow-up and facilitate immediate linkage to care/treatment
  - Cost-effective
- 
- Syphilis Health Check
    - Qualitative lateral flow immunochromatographic assay
    - The only FDA-cleared and CLIA-waived rapid syphilis test in the U.S.
    - Relatively new test (2011)
    - A need for improved understanding of test performance in various stages of syphilis, in context of co-infections (e.g. HIV), special and/or high risk populations



# Syphilis and HIV co-infection

Reported cases of primary and secondary syphilis by sex, sexual behavior, and HIV status, U.S. 2017




- High rate of HIV co-infection, particularly among MSM
- Among P&S syphilis cases with known HIV status:  
45.5% of MSM were HIV+ | 8.8% of MSW were HIV+ | 4.5% of women were HIV+

# HIV Cluster Investigation in W. Virginia

## BACKGROUND

Rates of reported primary and secondary syphilis cases by state, United States and outlying areas, 2017





# HIV Cluster Investigation in W. Virginia

## BACKGROUND

### Jan-Jul 2017

- **10 HIV+** cases in **3 counties**
- Injection drug use (IDU) area



### Jul 2017

- 9/10 HIV+ cases were MSM
  - 2/9 HIV+ MSM were IDU
- 5/10 HIV/syphilis+
- 3/10 HIV/Hep B+
- 2/10 HIV/Hep C+



### Sep 2017

- Contact tracing included **15 counties**




### Oct 2017

- **47 HIV+** cases
  - 87% male
  - 55% 20-29 yrs
  - 62% MSM
  - 11% IDU



HIV cluster by county, W. Virginia, 2017



Number of HIV diagnoses/month and cumulative number of diagnoses/year in 15 W. Virginia counties, 2015-2017

# Study Objectives

- Evaluate performance of rapid syphilis test in a high risk population
- Comparative assessment with traditional lab-based syphilis diagnostic serology tests

# Methods

27



Residual  
serum  
specimens



RPR



INNO-LIA



SHC



Trep-Sure



TP-PA


# Methods

- Specimen details blinded
- Manual RPR testing performed in W. Virginia; results blinded

27



Residual serum specimens



RPR



INNO-LIA



TP-PA








SHC



Trep-Sure

# Results

Diagnostic Test	Non-reactive	Reactive
 SHC	27/27	0/27
 RPR	27/27	0/27
 TP-PA	27/27	0/27
 Trep-Sure	27/27	0/27
 INNO-LIA	27/27	0/27

**Unblinded W. Virginia data:**

Non-reactive: 27/27

Reactive: 0/27

27 contacts from HIV+ confirmed cases

# Conclusions and Future Directions

- 100% specificity for Syphilis Health Check
  - All 27 residual serum specimens were non-reactive
  - No false positives
- Test sensitivity could not be evaluated
- Results in agreement with RPR results performed by W. Virginia W. Virginia Department of Health and Human Resources, Office of Laboratory Services
- Syphilis Health Check results in agreement with standard laboratory-based treponemal assays
- Findings may broaden understanding of rapid syphilis test performance in the context of outbreaks
- Evaluate performance using larger specimen set, as available
  - Determine correlations, if any, between rapid syphilis test results and co-infection(s) with HIV and other STIs

# Acknowledgements



## Division of HIV/AIDS Prevention

Christine Agnew-Brune  
Erica Dawson  
Paul J. Weidle  
Brooke E. Hoots

## Division of STD Prevention

Brunie B. White  
Yetunde Fakile  
Ellen Kersh  
Antoine Thompson  
Gloria De La Garza  
Anthony Gerard  
Lisa Varella  
Mike Granado  
Dawn Broussard  
Laura Quilter  
Alison D. Ridpath



Dondeena McGraw  
Technical Staff, Office of  
Laboratory Services



Oak Ridge Institute for Science & Education  
Josie Garcia

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

